PD-1+CD8+ T cells were activated rather than exhausted. PD-1+CD8+ T cells infiltrated muscle tissues. Affected muscles reacted to IFNγ, which could be produced from effector T cells, as a danger ...
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA priority ...
TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today ...
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback